SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-18-199509
Filing Date
2018-06-21
Accepted
2018-06-21 16:17:35
Documents
2
Group Members
LIAM RATCLIFFENEW LEAF BIOPHARMA OPPORTUNITIES I, L.P.NEW LEAF BPO ASSOCIATES I, L.P.NEW LEAF VENTURE ASSOCIATES III, L.P.NEW LEAF VENTURES III, L.P.RONALD M. HUNTVIJAY K. LATHI

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d591821dsc13da.htm SC 13D/A 155246
2 EX-99.A d591821dex99a.htm EX-99.A 11259
  Complete submission text file 0001193125-18-199509.txt   168458
Mailing Address C/O NEW LEAF VENTURE PARTNERS 7 TIMES SQUARE, SUITE 3502 NEW YORK NY 10036
Business Address C/O NEW LEAF VENTURE PARTNERS 7 TIMES SQUARE, SUITE 3502 NEW YORK NY 10036 646-871-6400
New Leaf Venture Management III, L.L.C. (Filed by) CIK: 0001625657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 500 TOTTEN POND ROAD WALTHAM MA 02451
Business Address 500 TOTTEN POND ROAD WALTHAM MA 02451 781-209-6400
Deciphera Pharmaceuticals, Inc. (Subject) CIK: 0001654151 (see all company filings)

IRS No.: 200299725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90130 | Film No.: 18912036
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences